MENU
+Compare
MDXXF
Stock ticker: OTC
AS OF
Jun 27 closing price
Price
$0.07
Change
-$0.00 (-0.00%)
Capitalization
8.48M

MDXXF PharmAla Biotech Holdings Inc. Forecast, Technical & Fundamental Analysis

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research... Show more

MDXXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MDXXF with price predictions
Jun 27, 2025

Momentum Indicator for MDXXF turns negative, indicating new downward trend

MDXXF saw its Momentum Indicator move below the 0 level on June 24, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator turned negative. In of the 43 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for MDXXF entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MDXXF's RSI Oscillator exited the oversold zone, of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for MDXXF just turned positive on June 27, 2025. Looking at past instances where MDXXF's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

MDXXF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.233) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). MDXXF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (20.704) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MDXXF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXXF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MDXXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
82 Richmond Street East
Phone
+1 855 444-6362
Employees
N/A
Web
https://www.pharmala.ca
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELRRF0.920.01
+1.11%
Eloro Resources Ltd.
OGFGY7.08N/A
N/A
Origin Energy Ltd.
SGBG10.60N/A
N/A
Signature Bank Georgia Sandy Springs
ARLLF81.21N/A
N/A
Argan Neuilly Sur Seine
MLPNF1.01N/A
N/A
MILLENNIAL POTASH CORP.

MDXXF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXXF has been loosely correlated with NICXF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXXF jumps, then NICXF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXXF
1D Price
Change %
MDXXF100%
+7.07%
NICXF - MDXXF
45%
Loosely correlated
N/A
ZIVO - MDXXF
22%
Poorly correlated
N/A
NGNE - MDXXF
20%
Poorly correlated
-2.47%
TRML - MDXXF
13%
Poorly correlated
-1.02%
ABVX - MDXXF
12%
Poorly correlated
+3.06%
More